---
document_datetime: 2025-12-02 06:07:54
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/medicines/human/EPAR/cablivi.html
document_name: cablivi.html
version: success
processing_time: 0.1154085
conversion_datetime: 2025-12-28 09:33:50.307094
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
# Cablivi

[RSS](/en/individual-human-medicine.xml/66605)

##### Authorised

This medicine is authorised for use in the European Union

caplacizumab Medicine Human Authorised

Page contents

## Page contents

- [Overview](#overview)
- [Product information](#product-info)
- [Product details](#product-details)
- [Authorisation details](#authorisation-details)
- [Assessment history](#assessment-history)
- [News on Cablivi](#news-on)
- [More information on Cablivi](#related-medicines)
- [Topics](#topics)

- Application under evaluation
- CHMP opinion
- European Commission decision

## Overview

Cablivi is a medicine for use in adults and children from 12 years of age weighing at least 40 kg and who have an episode of acquired thrombotic thrombocytopenic purpura (aTTP), a blood clotting disorder. During an episode of aTTP, blood clots form in small blood vessels and the patient has a low count of platelets (components that help the blood to clot).

Cablivi is used together with plasma exchange (a procedure that removes certain antibodies from the blood) and treatments to reduce the activity of the immune system (the body's defences).

Cablivi contains the active substance caplacizumab.

aTTP is rare, and Cablivi was designated an 'orphan medicine' (a medicine used in rare diseases) on 30 April 2009. Further information on the orphan designation: [EU/3/09/629](/en/medicines/human/orphan-designations/eu-3-09-629) .

Expand section

Collapse section

## How is Cablivi used?

Cablivi can only be obtained with a prescription. Treatment should be started and supervised by doctors experienced in managing patients who have clotting disorders affecting small blood vessels.

Cablivi is started with a dose of 10 mg given by injection into a vein before plasma exchange. Treatment is continued with 10 mg daily given by injection under the skin in the belly after daily plasma exchange and continued for 30 days after daily plasma exchange is stopped. Treatment with Cablivi may continue for longer if necessary. Patients also receive treatments to reduce the immune system's activity.

Patients or their carers may be able to inject Cablivi themselves after appropriate training.

For more information about using Cablivi, see the package leaflet or contact your doctor or pharmacist.

## How does Cablivi work?

In patients with aTTP, levels of a substance called von Willebrand factor are increased. Von Willebrand factor acts on platelets to cause them to stick together and form blood clots. Caplacizumab, the active substance in Cablivi, is a nanobody (a small antibody) which has been designed to attach to von Willebrand factor in a way that stops it acting on platelets. This reduces platelets sticking together and forming clots in blood vessels and, as a result, platelet levels in the blood rise because they are no longer taken up to form clots.

## What benefits of Cablivi have been shown in studies?

Two main studies have investigated the effectiveness of Cablivi in patients with aTTP who required plasma exchange to treat their condition. All patients were receiving standard treatment.

In the first study, involving 75 patients, platelet counts returned to the normal range after 3 days on average in patients treated with Cablivi, compared with nearly 5 days in those receiving placebo (a dummy treatment).

The second study, involving 145 patients, measured how long it took for the platelet count to return to the normal range and for sufficient improvement in the condition to allow daily plasma exchange to be stopped within 5 days. The study found that platelet count was likely to return to the normal range more quickly in patients treated with Cablivi compared with those receiving placebo.

Although the main studies only involved adults, the company provided additional modelling data indicating that the medicine will be as effective in children from 12 years of age who weigh at least 40 kg.

## What are the risks associated with Cablivi?

The most common side effects with Cablivi (which may affect more than 1 in 10 people) are nosebleeds, headache and bleeding from gums. For the full list of side effects and restrictions with Cablivi, see the package leaflet.

## Why is Cablivi authorised in the EU?

The European Medicines Agency decided that Cablivi's benefits are greater than its risks and it can be authorised for use in the EU. The Agency considered that, in patients with aTTP, Cablivi combined with plasma exchange and immunosuppression can reduce the time it takes for platelet counts to return to the normal range, which is associated with shorter duration of plasma exchange treatment and shorter stay in an intensive care facility. The most important side effect of treatment is bleeding but it is considered manageable. The company is expected to provide results of a study on Cablivi's safety and effectiveness over a longer period.

## What measures are being taken to ensure the safe and effective use of Cablivi?

The company that markets Cablivi will provide materials, including a patient alert card, on the risk of serious bleeding and how the risk should be managed.

Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Cablivi have also been included in the summary of product characteristics and the package leaflet.

As for all medicines, data on the use of Cablivi are continuously monitored. Side effects reported with Cablivi are carefully evaluated and any necessary action taken to protect patients.

## Other information about Cablivi

Cablivi received a marketing authorisation valid throughout the EU on 31 August 2018.

Cablivi : EPAR - Medicine overview

Reference Number: EMA/244353/2020

English (EN) (123.77 KB - PDF)

**First published:** 10/09/2018

**Last updated:** 22/06/2020

[View](/en/documents/overview/cablivi-epar-medicine-overview_en.pdf)

[Other languages (22)](#file-language-dropdown-762)

български (BG) (146.66 KB - PDF)

**First published:**

10/09/2018

**Last updated:**

22/06/2020

[View](/bg/documents/overview/cablivi-epar-medicine-overview_bg.pdf)

español (ES) (123.67 KB - PDF)

**First published:**

10/09/2018

**Last updated:**

22/06/2020

[View](/es/documents/overview/cablivi-epar-medicine-overview_es.pdf)

čeština (CS) (145.4 KB - PDF)

**First published:**

10/09/2018

**Last updated:**

22/06/2020

[View](/cs/documents/overview/cablivi-epar-medicine-overview_cs.pdf)

dansk (DA) (122.6 KB - PDF)

**First published:**

10/09/2018

**Last updated:**

22/06/2020

[View](/da/documents/overview/cablivi-epar-medicine-overview_da.pdf)

Deutsch (DE) (126.36 KB - PDF)

**First published:**

10/09/2018

**Last updated:**

22/06/2020

[View](/de/documents/overview/cablivi-epar-medicine-overview_de.pdf)

eesti keel (ET) (111.41 KB - PDF)

**First published:**

10/09/2018

**Last updated:**

22/06/2020

[View](/et/documents/overview/cablivi-epar-medicine-overview_et.pdf)

ελληνικά (EL) (146.36 KB - PDF)

**First published:**

10/09/2018

**Last updated:**

22/06/2020

[View](/el/documents/overview/cablivi-epar-medicine-overview_el.pdf)

français (FR) (124.71 KB - PDF)

**First published:**

10/09/2018

**Last updated:**

22/06/2020

[View](/fr/documents/overview/cablivi-epar-medicine-overview_fr.pdf)

hrvatski (HR) (144.16 KB - PDF)

**First published:**

10/09/2018

**Last updated:**

22/06/2020

[View](/hr/documents/overview/cablivi-epar-medicine-overview_hr.pdf)

italiano (IT) (121.95 KB - PDF)

**First published:**

10/09/2018

**Last updated:**

22/06/2020

[View](/it/documents/overview/cablivi-epar-medicine-overview_it.pdf)

latviešu valoda (LV) (152.75 KB - PDF)

**First published:**

10/09/2018

**Last updated:**

22/06/2020

[View](/lv/documents/overview/cablivi-epar-medicine-overview_lv.pdf)

lietuvių kalba (LT) (146.81 KB - PDF)

**First published:**

10/09/2018

**Last updated:**

22/06/2020

[View](/lt/documents/overview/cablivi-epar-medicine-overview_lt.pdf)

magyar (HU) (144.54 KB - PDF)

**First published:**

10/09/2018

**Last updated:**

22/06/2020

[View](/hu/documents/overview/cablivi-epar-medicine-overview_hu.pdf)

Malti (MT) (154.39 KB - PDF)

**First published:**

10/09/2018

**Last updated:**

22/06/2020

[View](/mt/documents/overview/cablivi-epar-medicine-overview_mt.pdf)

Nederlands (NL) (123 KB - PDF)

**First published:**

10/09/2018

**Last updated:**

22/06/2020

[View](/nl/documents/overview/cablivi-epar-medicine-overview_nl.pdf)

polski (PL) (147.3 KB - PDF)

**First published:**

10/09/2018

**Last updated:**

22/06/2020

[View](/pl/documents/overview/cablivi-epar-medicine-overview_pl.pdf)

português (PT) (123.34 KB - PDF)

**First published:**

10/09/2018

**Last updated:**

22/06/2020

[View](/pt/documents/overview/cablivi-epar-medicine-overview_pt.pdf)

română (RO) (143.92 KB - PDF)

**First published:**

10/09/2018

**Last updated:**

22/06/2020

[View](/ro/documents/overview/cablivi-epar-medicine-overview_ro.pdf)

slovenčina (SK) (144.95 KB - PDF)

**First published:**

10/09/2018

**Last updated:**

22/06/2020

[View](/sk/documents/overview/cablivi-epar-medicine-overview_sk.pdf)

slovenščina (SL) (143 KB - PDF)

**First published:**

10/09/2018

**Last updated:**

22/06/2020

[View](/sl/documents/overview/cablivi-epar-medicine-overview_sl.pdf)

Suomi (FI) (121.92 KB - PDF)

**First published:**

10/09/2018

**Last updated:**

22/06/2020

[View](/fi/documents/overview/cablivi-epar-medicine-overview_fi.pdf)

svenska (SV) (122.51 KB - PDF)

**First published:**

10/09/2018

**Last updated:**

22/06/2020

[View](/sv/documents/overview/cablivi-epar-medicine-overview_sv.pdf)

Cablivi : EPAR - Risk-management-plan summary

English (EN) (25.32 KB - PDF)

**First published:** 10/09/2018

**Last updated:** 10/09/2018

[View](/en/documents/rmp-summary/cablivi-epar-risk-management-plan-summary_en.pdf)

## Product information

Cablivi : EPAR - Product Information

English (EN) (686.58 KB - PDF)

**First published:** 10/09/2018

**Last updated:** 02/12/2024

[View](/en/documents/product-information/cablivi-epar-product-information_en.pdf)

[Other languages (24)](#file-language-dropdown-715)

български (BG) (722.15 KB - PDF)

**First published:**

10/09/2018

**Last updated:**

02/12/2024

[View](/bg/documents/product-information/cablivi-epar-product-information_bg.pdf)

español (ES) (661.3 KB - PDF)

**First published:**

10/09/2018

**Last updated:**

02/12/2024

[View](/es/documents/product-information/cablivi-epar-product-information_es.pdf)

čeština (CS) (465.58 KB - PDF)

**First published:**

10/09/2018

**Last updated:**

02/12/2024

[View](/cs/documents/product-information/cablivi-epar-product-information_cs.pdf)

dansk (DA) (588.86 KB - PDF)

**First published:**

10/09/2018

**Last updated:**

02/12/2024

[View](/da/documents/product-information/cablivi-epar-product-information_da.pdf)

Deutsch (DE) (810.34 KB - PDF)

**First published:**

10/09/2018

**Last updated:**

02/12/2024

[View](/de/documents/product-information/cablivi-epar-product-information_de.pdf)

eesti keel (ET) (456.76 KB - PDF)

**First published:**

10/09/2018

**Last updated:**

02/12/2024

[View](/et/documents/product-information/cablivi-epar-product-information_et.pdf)

ελληνικά (EL) (852.98 KB - PDF)

**First published:**

10/09/2018

**Last updated:**

02/12/2024

[View](/el/documents/product-information/cablivi-epar-product-information_el.pdf)

français (FR) (712.48 KB - PDF)

**First published:**

10/09/2018

**Last updated:**

02/12/2024

[View](/fr/documents/product-information/cablivi-epar-product-information_fr.pdf)

hrvatski (HR) (653.48 KB - PDF)

**First published:**

10/09/2018

**Last updated:**

02/12/2024

[View](/hr/documents/product-information/cablivi-epar-product-information_hr.pdf)

íslenska (IS) (674.6 KB - PDF)

**First published:**

10/09/2018

**Last updated:**

02/12/2024

[View](/is/documents/product-information/cablivi-epar-product-information_is.pdf)

italiano (IT) (667.48 KB - PDF)

**First published:**

10/09/2018

**Last updated:**

02/12/2024

[View](/it/documents/product-information/cablivi-epar-product-information_it.pdf)

latviešu valoda (LV) (615.88 KB - PDF)

**First published:**

10/09/2018

**Last updated:**

02/12/2024

[View](/lv/documents/product-information/cablivi-epar-product-information_lv.pdf)

lietuvių kalba (LT) (550.38 KB - PDF)

**First published:**

10/09/2018

**Last updated:**

02/12/2024

[View](/lt/documents/product-information/cablivi-epar-product-information_lt.pdf)

magyar (HU) (476.04 KB - PDF)

**First published:**

10/09/2018

**Last updated:**

02/12/2024

[View](/hu/documents/product-information/cablivi-epar-product-information_hu.pdf)

Malti (MT) (717.63 KB - PDF)

**First published:**

10/09/2018

**Last updated:**

02/12/2024

[View](/mt/documents/product-information/cablivi-epar-product-information_mt.pdf)

Nederlands (NL) (638.04 KB - PDF)

**First published:**

10/09/2018

**Last updated:**

02/12/2024

[View](/nl/documents/product-information/cablivi-epar-product-information_nl.pdf)

norsk (NO) (593.06 KB - PDF)

**First published:**

10/09/2018

**Last updated:**

02/12/2024

[View](/no/documents/product-information/cablivi-epar-product-information_no.pdf)

polski (PL) (699.74 KB - PDF)

**First published:**

10/09/2018

**Last updated:**

02/12/2024

[View](/pl/documents/product-information/cablivi-epar-product-information_pl.pdf)

português (PT) (679.42 KB - PDF)

**First published:**

10/09/2018

**Last updated:**

02/12/2024

[View](/pt/documents/product-information/cablivi-epar-product-information_pt.pdf)

română (RO) (689.16 KB - PDF)

**First published:**

10/09/2018

**Last updated:**

02/12/2024

[View](/ro/documents/product-information/cablivi-epar-product-information_ro.pdf)

slovenčina (SK) (962.94 KB - PDF)

**First published:**

10/09/2018

**Last updated:**

02/12/2024

[View](/sk/documents/product-information/cablivi-epar-product-information_sk.pdf)

slovenščina (SL) (713.27 KB - PDF)

**First published:**

10/09/2018

**Last updated:**

02/12/2024

[View](/sl/documents/product-information/cablivi-epar-product-information_sl.pdf)

Suomi (FI) (655.25 KB - PDF)

**First published:**

10/09/2018

**Last updated:**

02/12/2024

[View](/fi/documents/product-information/cablivi-epar-product-information_fi.pdf)

svenska (SV) (596.23 KB - PDF)

**First published:**

10/09/2018

**Last updated:**

02/12/2024

[View](/sv/documents/product-information/cablivi-epar-product-information_sv.pdf)

**Latest procedure affecting product information:** II/0050 22/11/2024

icon globe

<!-- image -->

This medicine's product information is available in all **official EU languages** . Select 'available languages' to access the language you need.

Product information documents contain:

- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).

Cablivi : EPAR - All Authorised presentations

English (EN) (68.8 KB - PDF)

**First published:** 10/09/2018

**Last updated:** 14/03/2019

[View](/en/documents/all-authorised-presentations/cablivi-epar-all-authorised-presentations_en.pdf)

[Other languages (24)](#file-language-dropdown-222)

български (BG) (47.91 KB - PDF)

**First published:**

10/09/2018

**Last updated:**

14/03/2019

[View](/bg/documents/all-authorised-presentations/cablivi-epar-all-authorised-presentations_bg.pdf)

español (ES) (44.69 KB - PDF)

**First published:**

10/09/2018

**Last updated:**

14/03/2019

[View](/es/documents/all-authorised-presentations/cablivi-epar-all-authorised-presentations_es.pdf)

čeština (CS) (46.94 KB - PDF)

**First published:**

10/09/2018

**Last updated:**

14/03/2019

[View](/cs/documents/all-authorised-presentations/cablivi-epar-all-authorised-presentations_cs.pdf)

dansk (DA) (46.46 KB - PDF)

**First published:**

10/09/2018

**Last updated:**

14/03/2019

[View](/da/documents/all-authorised-presentations/cablivi-epar-all-authorised-presentations_da.pdf)

Deutsch (DE) (48.46 KB - PDF)

**First published:**

10/09/2018

**Last updated:**

14/03/2019

[View](/de/documents/all-authorised-presentations/cablivi-epar-all-authorised-presentations_de.pdf)

eesti keel (ET) (44.34 KB - PDF)

**First published:**

10/09/2018

**Last updated:**

14/03/2019

[View](/et/documents/all-authorised-presentations/cablivi-epar-all-authorised-presentations_et.pdf)

ελληνικά (EL) (48.35 KB - PDF)

**First published:**

10/09/2018

**Last updated:**

14/03/2019

[View](/el/documents/all-authorised-presentations/cablivi-epar-all-authorised-presentations_el.pdf)

français (FR) (46.29 KB - PDF)

**First published:**

10/09/2018

**Last updated:**

14/03/2019

[View](/fr/documents/all-authorised-presentations/cablivi-epar-all-authorised-presentations_fr.pdf)

hrvatski (HR) (45.17 KB - PDF)

**First published:**

10/09/2018

**Last updated:**

14/03/2019

[View](/hr/documents/all-authorised-presentations/cablivi-epar-all-authorised-presentations_hr.pdf)

íslenska (IS) (45.99 KB - PDF)

**First published:**

10/09/2018

**Last updated:**

14/03/2019

[View](/is/documents/all-authorised-presentations/cablivi-epar-all-authorised-presentations_is.pdf)

italiano (IT) (69.26 KB - PDF)

**First published:**

10/09/2018

**Last updated:**

14/03/2019

[View](/it/documents/all-authorised-presentations/cablivi-epar-all-authorised-presentations_it.pdf)

latviešu valoda (LV) (46.22 KB - PDF)

**First published:**

10/09/2018

**Last updated:**

14/03/2019

[View](/lv/documents/all-authorised-presentations/cablivi-epar-all-authorised-presentations_lv.pdf)

lietuvių kalba (LT) (70.09 KB - PDF)

**First published:**

10/09/2018

**Last updated:**

14/03/2019

[View](/lt/documents/all-authorised-presentations/cablivi-epar-all-authorised-presentations_lt.pdf)

magyar (HU) (46.2 KB - PDF)

**First published:**

10/09/2018

**Last updated:**

14/03/2019

[View](/hu/documents/all-authorised-presentations/cablivi-epar-all-authorised-presentations_hu.pdf)

Malti (MT) (45.86 KB - PDF)

**First published:**

10/09/2018

**Last updated:**

14/03/2019

[View](/mt/documents/all-authorised-presentations/cablivi-epar-all-authorised-presentations_mt.pdf)

Nederlands (NL) (45.3 KB - PDF)

**First published:**

10/09/2018

**Last updated:**

14/03/2019

[View](/nl/documents/all-authorised-presentations/cablivi-epar-all-authorised-presentations_nl.pdf)

norsk (NO) (47.89 KB - PDF)

**First published:**

10/09/2018

**Last updated:**

14/03/2019

[View](/no/documents/all-authorised-presentations/cablivi-epar-all-authorised-presentations_no.pdf)

polski (PL) (48.01 KB - PDF)

**First published:**

10/09/2018

**Last updated:**

14/03/2019

[View](/pl/documents/all-authorised-presentations/cablivi-epar-all-authorised-presentations_pl.pdf)

português (PT) (46.82 KB - PDF)

**First published:**

10/09/2018

**Last updated:**

14/03/2019

[View](/pt/documents/all-authorised-presentations/cablivi-epar-all-authorised-presentations_pt.pdf)

română (RO) (45.28 KB - PDF)

**First published:**

10/09/2018

**Last updated:**

14/03/2019

[View](/ro/documents/all-authorised-presentations/cablivi-epar-all-authorised-presentations_ro.pdf)

slovenčina (SK) (47.85 KB - PDF)

**First published:**

10/09/2018

**Last updated:**

14/03/2019

[View](/sk/documents/all-authorised-presentations/cablivi-epar-all-authorised-presentations_sk.pdf)

slovenščina (SL) (45.44 KB - PDF)

**First published:**

10/09/2018

**Last updated:**

14/03/2019

[View](/sl/documents/all-authorised-presentations/cablivi-epar-all-authorised-presentations_sl.pdf)

Suomi (FI) (43.53 KB - PDF)

**First published:**

10/09/2018

**Last updated:**

14/03/2019

[View](/fi/documents/all-authorised-presentations/cablivi-epar-all-authorised-presentations_fi.pdf)

svenska (SV) (46.61 KB - PDF)

**First published:**

10/09/2018

**Last updated:**

14/03/2019

[View](/sv/documents/all-authorised-presentations/cablivi-epar-all-authorised-presentations_sv.pdf)

## Product details

Name of medicine Cablivi Active substance Caplacizumab International non-proprietary name (INN) or common name caplacizumab Therapeutic area (MeSH) Purpura, Thrombotic Thrombocytopenic Anatomical therapeutic chemical (ATC) code B01A

### Pharmacotherapeutic group

Antithrombotic agents

### Therapeutic indication

Cablivi is indicated for the treatment of adults experiencing an episode of acquired thrombotic thrombocytopenic purpura (aTTP), in conjunction with plasma exchange and immunosuppression.

## Authorisation details

EMA product number EMEA/H/C/004426

Orphan

This medicine was designated an orphan medicine. This means that it was developed for use against a rare, life-threatening or chronically debilitating condition or, for economic reasons, it would be unlikely to have been developed without incentives. For more information, see [Orphan designation](/node/69983) .

Marketing authorisation holder

Ablynx NV

Technologiepark 21

Opinion adopted 31/05/2018 Marketing authorisation issued 30/08/2018 Revision 9

## Assessment history

Expand section

Collapse section

## Changes since initial authorisation of medicine

Cablivi : EPAR - Procedural steps taken and scientific information after authorisation

English (EN) (217.51 KB - PDF)

**First published:** 04/12/2018

**Last updated:** 02/12/2024

[View](/en/documents/procedural-steps-after/cablivi-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf)

Cablivi-H-C-4426-II-0021: EPAR - Assessment report - Variation

Adopted

English (EN) (619.21 KB - PDF)

**First published:** 22/06/2020

[View](/en/documents/variation-report/cablivi-h-c-4426-ii-0021-epar-assessment-report-variation_en.pdf)

CHMP post-authorisation summary of positive opinion for Cablivi (II-21)

Adopted

Reference Number: EMA/CHMP/227535/2020

English (EN) (127.68 KB - PDF)

**First published:** 30/04/2020

[View](/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-cablivi-ii-21_en.pdf)

## Initial marketing authorisation documents

Cablivi : Orphan maintenance assessment report (initial authorisation)

Reference Number: EMA/541816/2018

English (EN) (361.84 KB - PDF)

**First published:** 10/09/2018

**Last updated:** 10/09/2018

[View](/en/documents/orphan-maintenance-report/cablivi-orphan-maintenance-assessment-report-initial-authorisation_en.pdf)

Cablivi : EPAR - Public assessment report

Reference Number: EMA/490172/2018

English (EN) (2.26 MB - PDF)

**First published:** 10/09/2018

**Last updated:** 10/09/2018

[View](/en/documents/assessment-report/cablivi-epar-public-assessment-report_en.pdf)

CHMP summary of positive opinion for Cablivi

Adopted

Reference Number: EMA/CHMP/419463/2018

English (EN) (69.7 KB - PDF)

**First published:** 29/06/2018

**Last updated:** 29/06/2018

[View](/en/documents/smop-initial/chmp-summary-positive-opinion-cablivi_en.pdf)

#### News on Cablivi

[Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 28-30 April 2020](/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-28-30-april-2020) 30/04/2020

[Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 25-28 June 2018](/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-25-28-june-2018) 29/06/2018

#### More information on Cablivi

- [EU/3/09/629 - orphan designation for treatment of thrombotic thrombocytopenic purpura](/en/medicines/human/orphan-designations/eu-3-09-629)

#### Topics

- [Medicines](https://www.ema.europa.eu/en/search?f%5B0%5D=ema_search_topics%3A61)

**This page was last updated on** 02/12/2024

## Share this page

[Back to top](#main-content)